J&J touts long list of advanced drug candidates

The Wall Street Journal reports that Johnson & Johnson has been touting a fattened drug pipeline to Wall Street. The drug giant has told analysts that it has 17 drugs that are either in advanced clinical trials or awaiting approval. Four years ago in its last Wall Street review the company had two advanced drugs. Among its most promising candidates are dapoxetine for premature ejaculation, the antipsychotic paliperidone and Yondelis. Johnson & Johnson has also set its sites on supplying drugs for HIV/AIDS.

- read this story from AFX for more on the pipeline

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.